Translational Research

Shared Resources

Purpose

The overall goal of the Translational Research Core (TRC) is to provide a high quality resource and state-of-the-art services for measuring pharmacokinetic drug levels of novel and standard chemotherapeutic agents in preclinical animal studies and in clinical studies, and to quantify pharmacodynamic endpoints in preclinical studies as well as for early phase clinical trials. Drug quantitation is achieved through liquid chromatography-tandem mass spectrometry workflows using biological fluids (e.g., blood, serum, urine) and other tissues, including tumors.  These measurements can be taken further downstream to produce useful pharmacokinetic data. 

Molecular endpoints are obtained through select core immunoassay services using whole cells, cell/tumor extracts or biological fluids. High-throughput, cell-based drug screening assays with multidrug synergy analysis can be used in a preclinical setting or as part of clinical correlative studies. Additional services supporting pre-clinical experimentation include cell-line drug quantitation and pharmacokinetic analysis. Major technical services offered by TRC are Drug Quantitation, Pharmacokinetic Analysis, Drug Response Assays and Pharmacodynamic Analytical Services.

The TRC offers a full line of services within these major categories and the ability to work with investigators through collaborative design, to develop and implement both translational science and clinical science experiments in the core under the umbrella of services. In addition, a major function of the TRC is dedicated to consultation services to Members ranging from experimental design to interpretation of data. The core consists of five full-time highly trained staff members. These kinetic and dynamic services provide cancer center members with invaluable resources to conduct research and play a significant role in establishing the cancer center as a leader in clinical and translational research.

Services

TRC services include specialized sample processing for research specimens collected in clinical trials and a variety of pharmacologic, whole cell-based and molecular assays:   

Pharmacokinetic Services
Drug Quantitation (free and total)
                  Clinical Research
                  Pre-clinical (murine)
                  Metabolic Stability/Inhibition Studies                  
                  Basic Science (cell lines)
Pharmacokinetic Analysis
                  Non-Compartmental & Compartmental Analysis

Pharmacodynamic Services
Molecular Endpoint Analysis
                  Hematologic Subset Enrichment
                  Flow/PhosFlow Setup
                  Western Blotting/EMSA
                  ELISA and CBA/Luminex Setup
Drug Screening/Drug Interaction Analysis
                  384- and 1536-well Plate - Cell Based Assays
                  Viability/Cytotoxicity/Apoptosis IC50 Analysis
                  Drug Synergy/Antagonism Analysis (EoHSA/CI)

Please contact the Core by phone or email for more details on current services and pricing.              

Core Facility Manager:
Anthony Neuger, MS
anthony.neuger@moffitt.org
813-745-2288

Pharmacokinetic Services:
Research Specialist - Samer Sansil, MS
samer.sansil@moffitt.org
813-745-5759

Pharmacodynamic Services:
Staff Scientist - Chris Cubitt, PhD
christopher.cubitt@moffitt.org
813-745-3687

Core Staff:
Research Specialist - Shumin Zhang, MD
Research Specialist - Ashley Blanchard, BS

Location
The Translational Research Core is located in the Moffitt Research Center (MRC) on the first floor, rooms 1304 & 1305.

Scheduling
The Translational Research core uses a Laboratory Information Management Suite (LIMS) located on the Moffittnet for billing and usage tracking.

Publications

All publications based on work conducted in the Translational Research Core should acknowledge the facility. A suggested statement is as follows:

This work has been supported in part by the Translational Research Core at the H. Lee Moffitt Cancer Center & Research Institute, a comprehensive cancer center designated by the National Cancer Institute and funded in part by Moffitt’s Cancer Center Support Grant (P30-CA076292)

If a Core Staff member(s) significantly contributes or participates in a project, investigators are encouraged to consider including the individual(s) in the list of authors.